Loghman Sharifi - Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran
Hosein Rostami - Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
Mehran Rahimlou - Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences,Ahvaz,Iran
Azadeh Dehghani Kari Bozorg - Department of Community Nutrition, School of Nutritional Sciences and Dietetics, international campus,Tehran University of Medical Sciences (TUMS), Tehran, Iran

Background and Aim: Numerous studies evidenced that conjugated linoleic acid (CLA) could effect on several diabetes related factors but finding was ControversialMethods: We searched the PubMed, Web of Science, Cochrane, Scopus and and the ClinicalTrials.gov up to January 2017. We used from a random-effects model to calculate the combined treatment effectsResults: Four studies which involved 116 participants were included in final analysis. CLA dose ranging from 3 to 6.4 mg/day. Compared with placebo, the pooled estimate of change was -1.28 (95% CI: -3.66, 1.10), 0.38 (95% CI: -0.26, 1.03), 0.00 (95% CI: -0.01, 0.01) and 0.03 (95% CI: -17.31, 17.26) for HOMA-IR, HbA1c, QUICKI and FBS Respectively. Conclusion: The finding of this study was not support for benfecial effect of CLA in diabetic patients.

Conjugated linoleic acid, CLA, T2DM, blood glucose, Meta-analysis